EXIBIT: Oxaliplatin in Biliary Tract Cancer
The primary objective is to evaluate the efficacy of the GEMOX treatment as 1st line therapy in patients with advanced biliary tract cancer based on response rate measured by the RECIST unidimensional criteria.

Secondary objectives are : Progression free survival, overall survival and safety.
Biliary Tract Neoplasms
DRUG: oxaliplatin
To evaluate response rate according to RECIST criteria
To evaluate the progression-free survival in the ITT population|To investigate safety using NCI-CTC criteria version 2
The primary objective is to evaluate the efficacy of the GEMOX treatment as 1st line therapy in patients with advanced biliary tract cancer based on response rate measured by the RECIST unidimensional criteria.

Secondary objectives are : Progression free survival, overall survival and safety.